ADMA BiologicsvsJohnson & Johnson

ADMA and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

ADMA

ADMA Biologics Inc

$13.98

Value $3.1B

+2.60%
ADMA's page

ADMA Biologics (ADMA) has a market value of $3.1B and Johnson & Johnson (JNJ) $666B. Over the last year, with dividends, ADMA moved -9.3% and JNJ +41.6%. The P/E is 17.0 for ADMA and 41.4 for JNJ. Dividend yield: ADMA none, JNJ 1.91%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ADMA$3.1B

    JNJ$666B

    JNJ is 215 times ADMA

  • Revenue, 12 months

    ADMA$519M

    JNJ$99.3B

    JNJ is 191 times ADMA

  • Net income, 12 months

    ADMA$182M

    JNJ$16.1B

    JNJ is 88 times ADMA

  • Operating margin

    ADMA46.5%

    JNJ–

  • ROIC

    ADMA32.6%

    JNJ12.4%

    20.2 points apart

  • P/E

    ADMA17.0

    JNJ41.4

    JNJ is 2.4 times ADMA

  • Dividend yield

    ADMA0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    ADMA+832.0%

    JNJ+94.6%

    737.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ADMA+832.1%

JNJ+94.6%

05001000150020222023202420252026
Returns by period
PeriodADMAWith dividendsJNJWith dividends
1 year since November 17, 2025-9.3%Price -9.3%+41.6%Price +38.5%
3 years since November 17, 2023+252.1%+52.1% a yearPrice +252.1%+101.0%+26.2% a yearPrice +84.6%
5 years since November 17, 2021+832.0%+56.3% a yearPrice +832.0%+94.6%+14.2% a yearPrice +69.3%
10 years since November 18, 2016+147.0%+9.5% a yearPrice +147.0%+212.3%+12.1% a yearPrice +139.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ADMAADMA BiologicsJNJJohnson & Johnson

Valuation

ADMAJNJ
Valuation
Price$13.98$276.43
Market value$3.1B$666B
Enterprise value (EV)$3.2B$694B
P/E17.041.4
P/E, 5-year median–21.9
P/B7.18.2
EV/EBIT13.239.1
Free cash flow yield4.3%3.1%

Results and growth

ADMAJNJ
Results and growth
Revenue, 12 months$519M$99.3B
Net income, 12 months$182M$16.1B
Free cash flow, 12 months$133M$20.6B
Earnings per share, 12 months$0.77$6.59
Revenue growth, year on year19.6%6.1%
Revenue growth a year, past+64.6%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

ADMAJNJ
Margins and returns on capital
Gross margin68.5%67.6%
Operating margin46.5%–
Net margin35.1%16.2%
ROIC32.6%12.4%
ROE42.5%19.7%

Balance sheet

ADMAJNJ
Balance sheet
Cash$125M$17.2B
Total debt$203M$44.7B
Net debt / EBITDA0.31.1
Interest cover22.8×18.0×

Dividends and buybacks

ADMAJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield1.0%0.9%
Shareholder yield1.0%2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ADMA or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, ADMA Biologics or Johnson & Johnson?

By market value, Johnson & Johnson ($666B) is about 214.7 times ADMA Biologics ($3.1B), at today's prices.

How did ADMA and JNJ stock do over the last 10 years?

Since November 18, 2016, ADMA's price moved +147.0% and JNJ's +139.6%. With dividends: ADMA +147.0% (+9.5% a year), JNJ +212.3% (+12.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, ADMA or JNJ?

The dividend yield at today's price is none for ADMA Biologics and 1.91% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of ADMA and JNJ?

At today's price, the P/E is 17.0 for ADMA and 41.4 for JNJ. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, ADMA Biologics or Johnson & Johnson?

Over the last twelve months, the net margin was 35.1% for ADMA Biologics and 16.2% for Johnson & Johnson, and the operating margin 46.5% and –. Revenue was $519M and $99.3B.

Which is the better investment, ADMA Biologics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.